Zetagen Therapeutics, Inc. Receives Australian Patent Issuance for Treatment of Stimulating Bone Growth
July 23, 2020, (Syracuse, New York) - private, clinical-stage, biopharmaceutical company
dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and
orthopedic interventions, announced today that the Australian Government has issued Patent No.
2015267006 to the Company. The patent, entitled Composition and Methods to Promote Bone
Formation, covers the use of methods for stimulating bone growth using the Company’s small
molecule, ZetaMet™ (Zeta-BC-003).